{
    "nct_id": "NCT06651281",
    "official_title": "A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis",
    "inclusion_criteria": "* Has participated in a qualifying tulisokibart Phase 2 or Phase 3 parent study for CD or UC\n* The investigator determines that the participant derives clinical benefit from continued study intervention based upon clinical evaluations performed during their parent study\n* A participant assigned female sex at birth is not breastfeeding during the study intervention period and for at least 14 weeks after the last dose of study intervention\n* A participant of childbearing potential (POCBP) is not pregnant and has a negative highly sensitive pregnancy test (urine or serum) as required by local regulations within 24 hours (for a urine test) or 72 hours (for a serum test) before the first dose of study intervention\n* A POCBP uses an acceptable contraceptive method, or adheres to penile-vaginal intercourse abstinence as their preferred and usual lifestyle (abstinent on a long-term and persistent basis)\nHealthy volunteers allowed",
    "exclusion_criteria": "* Has prematurely discontinued study intervention in their parent study\n* Has received any protocol-specified prohibited medications during their parent study\n* Has known allergies, hypersensitivity, or intolerance to tulisokibart or its excipients",
    "miscellaneous_criteria": ""
}